The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Endometrial cancer becomes a three-horse race
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
ASCO 2024 – Blenrep “should return” to the US
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
